Owner Scorecard


← All companies ← AXS Manual AXTA → ← AVTX Pharmaceuticals AZN →

AXSM, Axsome Therapeutics Inc.

Pharmaceuticals consumer brand UnprofitableDistress / turnaround

We are a biopharmaceutical company dedicated to the development and commercialization of innovative medicines for people impacted by central nervous system conditions.

We are also advancing a pipeline of novel product candidates addressing a broad range of serious neurological and psychiatric conditions, including narcolepsy, fibromyalgia, and ADHD.

Business" for a summary of our marketed products and clinical development programs.

Latest annual: FY2025 10-K
AXSM · Axsome Therapeutics Inc.
I

The business

What it sells, where the money comes from, the kind of company it is.

Revenue · FY2025
$638M
+65.5% YoY · 134% 3-yr CAGR
Vital signs · TTM, with 4-yr average
Revenue $708M 4-yr avg $336M
Operating margin −24.4% 4-yr avg −136.0%
Owner-earnings margin −10% 4-yr avg −84%
Free cash flow margin −10% 4-yr avg −84%

The business in brief

read the 10-K →

What this business is and what moves its needle, from its own SEC filings.

Situation
Unprofitable. No sustained operating profit across the record; an earnings multiple has nothing to rest on. What the record does show is revenue, the gross-margin trajectory, and the burn against the cash on hand. Distress / turnaround. Thin interest coverage, or operating cash burned against real debt, across the record. The balance sheet carries this situation; the debt schedule sets the clock.
What moves the needle
Operating margin has run around −86% through the cycle, the operating line deeply negative — so the lever is the path to a margin at all: revenue growth against the cost curve and the cash runway, not the level of a margin that isn't there yet. Stock-based pay runs about 22% of sales, a real and recurring claim on owners that the GAAP margin understates. Read this kind of business on the pipeline against the patent cliff, and pricing. On its own account, the filing leans hardest on litigation & contingencies, set against the numbers in what the filing emphasizes, below.

Every line is arithmetic on the company's filings, shown in full in the sections below.

II

The record

Ten years of arithmetic, read across the cycle.

The record, 2022–2025

realized figures from each filing · older years to the left
2022’222023’232024’242025’25TTMTTMMar 2026
Income statement
$50M$271M$386M$638M$708MRevenueRevenue
90%99%Gross marginGross mgn
318%119%107%89%90%SG&A / revenueSG&A/rev
116%36%49%29%27%R&D / revenueR&D/rev
($180M)($232M)($281M)($167M)($173M)Operating incomeOp. inc.
−359.3%−85.7%−72.7%−26.1%−24.4%Operating marginOp. mgn
($187M)($239M)($287M)($183M)($188M)Net incomeNet inc.
Cash flow & returns
($117M)($145M)($128M)($93M)($71M)Operating cash flowOp. cash
$263K$459K$532K$503K$470KDepreciationDeprec.
$33M$31M$73M($4M)$23MWorking capital & otherWC & other
$702K$582K$270K$480K$263KCapexCapex
1.4%0.2%0.1%0.1%0.0%Capex / revenueCapex/rev
($117M)($146M)($129M)($94M)($71M)Owner earningsOwner earn.
−233.4%−53.8%−33.4%−14.7%−10.0%Owner earnings marginOE mgn
($117M)($146M)($129M)($94M)($71M)Free cash flowFCF
−234.3%−53.8%−33.4%−14.7%−10.0%Free cash flow marginFCF mgn
$53M$53MAcquisitionsAcquis.
-171%-125%-504%-207%-345%Return on equityROE
−171%−125%−504%−207%−345%Retained to equityRetained/eq
Balance sheet
$201M$386M$315M$323M$305MCash & investmentsCash+inv
$38M$95M$142M$224M$251MReceivablesReceiv.
$4M$15M$16M$28M$32MInventoryInvent.
$39M$41M$72M$66M$107MAccounts payablePayables
$3M$69M$86M$187M$176MOperating working capitalOper. WC
$246M$504M$485M$589M$611MCurrent assetsCur. assets
$97M$139M$230M$379M$439MCurrent liabilitiesCur. liab.
2.5×3.6×2.1×1.6×1.4×Current ratioCurr. ratio
$10M$12M$12M$12M$12MGoodwillGoodwill
$331M$588M$568M$690M$714MTotal assetsAssets
$94M$178M$181M$188M$188MTotal debtDebt
($107M)($208M)($135M)($135M)($117M)Net debt / (cash)Net debt
$110M$191M$57M$88M$55MShareholders’ equityEquity
75.4%23.1%22.1%14.7%13.3%Stock comp / revenueSBC/rev
Per share
40.7M45.4M47.9M49.7M51.2MShares out (diluted)Shares
$1.23$5.96$8.05$12.83$13.83Revenue / shareRev/sh
$-4.60$-5.27$-5.99$-3.68$-3.68EPS (diluted)EPS
$-2.87$-3.20$-2.69$-1.89$-1.39Owner earnings / shareOE/sh
$-2.88$-3.21$-2.69$-1.89$-1.39Free cash flow / shareFCF/sh
$0.02$0.01$0.01$0.01$0.01Cap. spending / shareCapex/sh
$2.69$4.20$1.19$1.77$1.07Book value / shareBVPS
Per-share growththe realized rate an owner's share compounded
3-yr5-yr
Revenue / share+118.5%/yr+118.5%/yr (3-yr)
Capital spending / share−17.6%/yr−17.6%/yr (3-yr)
Book value / share−13.0%/yr−13.0%/yr (3-yr)

The record, charted

FY2022–2025

Each measure over its full record; the current point and the worst year marked.

Share count
50Mpeak FY2025

Owner earnings vs. net income

Owner earningsNet income

The accountant's number, and the cash an owner can take; the gap is the tell.

($94M)owner earningsvs.($183M)net incomelow FY2023

Net income is the accountant's number; owner earnings is the cash an owner could take out. The walk between them, off the cash-flow statement, and whether the gap is widening or holding.

In fiscal 2025 the business turned a $183M loss into ($94M) of owner earnings: more cash than the profit line showed, after the non-cash charges and the capital it put back in.

FY2025FY2024FY2023FY2022
Reported net income($183M)($287M)($239M)($187M)
Depreciation & amortizationnon-cash charge added back+$503K+$532K+$459K+$263K
Stock-based compensationreal costnon-cash, but a real cost+$94M+$85M+$63M+$38M
Working capital & othertiming of cash in and out, other non-cash items−$4M+$73M+$31M+$33M
Cash from operations($93M)($128M)($145M)($117M)
Maintenance capital expenditurethe spending needed just to hold position and volume−$480K−$270K−$459K−$263K
Owner earnings($94M)($129M)($146M)($117M)
Growth capital expenditurediscretionary; spent to get bigger, not to stand still−$123K−$439K
Free cash flow($94M)($129M)($146M)($117M)
Owner-earnings marginowner earnings ÷ revenue-15%-33%-54%-233%

Owner earnings is the cash an owner could pull out without starving the business: operating cash less the capital it must spend to hold its position . The cash-flow statement also adds stock comp back as non-cash, but it is a real cost paid in shares; counted as the expense it is (less $94M), owner earnings is nearer ($188M).

Maintenance capex is estimated as depreciation where a growing business invests above it; free cash flow is the figure the scorecard's free-cash margin reads.

III

Quality & stewardship

Returns, the balance sheet, capital allocation, and pay.

Owner’s Scorecard

FY2025 10-K · source on SEC EDGAR →

Will it survive?

  • No meaningful interest burden
    Little or no interest expense reported
    What this means

    Little or no interest expense reported, the business isn't leaning on lenders to operate.

  • Net cash
    Cash $323M − debt $188M
    What this means

    Cash and short-term investments exceed every dollar of debt by $135M, on net the company owes nothing, and can act from strength when others can't. Net debt is the leverage figure that matters: the cash is already set against the debt. Strategic or illiquid investments aren't counted here.

  • Negative, funded by others
    DSO 128 + DIO 1961 − DPO 4600 days
    What this means

    Days cash is tied up between paying suppliers and collecting from customers. A negative cycle is a quiet moat: suppliers and customers fund the operation (Buffett's “float”), the company grows on other people's money.

Is it a good business?

  • Not meaningful here
    Invested capital ($47M) = debt $188M + equity $88M − cash
    Industry peers: median -8%
    What this means

    Invested capital is near zero or negative, usually years of buybacks pulling equity down. ROIC explodes or flips sign and stops meaning anything. Judge this one on Owner Earnings instead.

  • Consumes cash through the cycle
    4-yr median margin, range -233%–-15%; latest ($94M) = operating cash ($93M) − maintenance capex $480K
    Industry peers: median -13%
    What this means

    What an owner could take out without starving the business: operating cash less the maintenance capital it must spend to hold its position — Buffett's owner earnings. That's -15% of revenue this year, a -54% median across 4 years. Treating stock comp as the real expense it is (less $94M of SBC) leaves ($188M).

  • Loss, and burning cash
    Net income ($183M) · cash from operations ($93M)
    What this means

    The company reported a net loss, so a conversion ratio isn't meaningful. What matters then is whether operations still threw off cash, here, they did not.

How is the cash used?

  • Not enough data
    What this means

    The filing data didn't include the inputs for this check.

  • Investing or harvesting? 0.95×
    Maintaining
    Capex $480K ÷ depreciation $503K
    What this means

    Descriptive, not a grade. Above ~1× means investing faster than assets wear out (growth, or, sustained for years, today's earnings carrying less depreciation than tomorrow's will). Below means spending less than it's wearing out (efficiency, or a melting asset base). The ratio won't tell you which; the filings will.

Graham’s defensive tests · 1 of 3 met

Graham’s numerical criteria for the defensive investor (The Intelligent Investor, ch. 14), run on the filings. A floor of safety, not a buy signal; many fine modern businesses fail his strictest liquidity rules by design.

  • Adequate size Miss
    Revenue ≥ $2B · $638M
    What this means

    Big enough to weather a storm. Graham's 1972 floor was ~$100M of sales (≈ $700M today); we use a $2B revenue line as a conservative modern stand-in.

  • Strong liquidity Near
    Current ratio ≥ 2× · 1.55×
    What this means

    Current assets at least twice current liabilities, near-term bills covered without touching the business. Strict by design: many cash-rich modern firms run leaner and miss it, holding their cushion in longer-dated securities.

  • Conservative debt Pass
    Debt ≤ working capital · $188M vs $210M WC
    What this means

    Graham's rule that borrowings not exceed net current assets. Capital-heavy and buyback-heavy firms routinely fail it, read it next to interest coverage, not alone.

  • Moderate price
    P/E ≤ 15 and P/E × P/B ≤ 22.5 · decided by the price
    What this means

    Graham's valuation gate, the wall he kept between a sound business and a sound investment. Three-year average earnings are $-4.60/share (latest year $-3.56), the averaged base the calculator's gate runs on, and book value is $1.72/share. Enter a price in “What the price implies” just below for the P/E, P/B, and whether it clears. But this is the rule Buffett outgrew: there's no hard P/E law, and a wonderful business can deserve a far richer multiple if the thesis holds, treat it as the bargain-hunter's floor, not a verdict on the price.

Durability & moat, 2022–2025

Whether the record’s returns held, and what the capital reinvested earned.

  • Profitable years 0 of 4
    What this means

    Lost money in 4 year(s), look at what happened there before trusting the average.

  • Operating margin −223% → −49% (2-yr avg ends)
    What this means

    Through the cycle the operating margin widened — about −223% early to −49% lately, median −86% — pricing power intact or improving.

  • Reinvestment, incremental ROIC returns capital
    What this means

    The capital base barely grew: this business returns cash through dividends and buybacks rather than reinvesting. Judge it on the cash returned, not on compounding.

  • Worst year 2022 · −359.3% op. margin
    What this means

    Operations went underwater in 2022, understand why before trusting the good years.

  • Share count +7.0%/yr
    What this means

    The share count is rising, dilution works against you on a per-share basis.

Does AI threaten the moat?

Low contestability

The moat is physical, regulated or balance-sheet-funded, the kind AI cuts costs within but does not contest.

AI is unlikely to contest a moat that is physical, regulated or balance-sheet-funded; here it reads more as a cost tool than a threat.

Read from the filing's own risk factors, paired with the industry's structure under its SIC code; the durability is read above, the price below.

All figures as filed; the source filing is linked above.

Current Position

as of the latest quarter, Mar 31, 2026

Can the business pay what it owes this year, off the freshest balance sheet: the quality of the assets, the debt actually coming due, and what a low ratio means here.

Current assets$611M
  • Cash & short-term investments$305M
  • Receivables$251M
  • Inventory$32M
  • Other current assets$24M
Current liabilities$439M
  • Debt due within a year$70M
  • Accounts payable$107M
  • Other current liabilities$263M
Current ratio1.39×all current assets ÷ what's due · Graham looked for 2×
Quick ratio1.32×stricter: inventory excluded
Cash ratio0.69×strictest: cash alone against what's due
Working capital$172Mthe cushion left after near-term bills
Debt due this year vs. cash$70M due · $305M cash covered by cash on hand, no refinancing forced · both figures from the Mar 31, 2026 balance sheet
Cash runway4.3 yrsthe business is consuming cash; this is how long the cash on hand lasts at that rate
Revenue, latest quarter vs. a year ago+57.4%the freshest read on whether the business is still growing
Current ratio, recent quarters2.5× → 1.4×
Deeper floors
Tangible book value$4Mequity stripped of goodwill & intangibles
Net current asset value($48M)Graham's net-net: current assets less all liabilities
Debt incl. operating leases$211M$23M of it operating leases

From the company's latest filing.

Management, ownership & pay

read the proxy →

From the proxy: how much of the business the people running it own, and how they are paid, beside what the business earned for its owners in the same years.

Fiscal yearChief executivePay, as filed“Actually paid”Owner earnings
2021Herriot Tabuteau, M.D.$8.1M−$11.1M
2022Herriot Tabuteau, M.D.$8.3M$28.0M($117M)
2023Herriot Tabuteau, M.D.$9.9M$9.6M($146M)
2024Herriot Tabuteau, M.D.$10.4M$10.1M($129M)
2025Herriot Tabuteau, M.D.$10.3M$33.8M($94M)

Both pay figures are the company’s own, from the pay-versus-performance table its proxy statement files. “As filed” is the Summary Compensation Table total: salary, bonus, and equity awards at their value on the day of grant. “Actually paid” is the SEC’s prescribed recalculation, which re-marks those equity awards to what they became as they vested; it can swing far above or below the filed figure in either direction, and negative years occur. Owner earnings are the whole business's, from the record above, for the same fiscal years.

  • Insider ownership20.6%

    The stake all directors and executive officers hold together, per the 2026 proxy: skin in the game, the first thing Munger reads.

  • CEO pay ratio23:1

    What the chief earns for every dollar the median employee makes, per the 2026 proxy. A high ratio alone settles nothing; some businesses are genuinely top-heavy in scarce skill. A runaway figure is where Buffett starts asking whether the board is doing its job.

  • Stock-based compensation$94M

    The slice of the business handed to employees in shares this year, 15% of revenue. Buffett's oldest accounting fight: this is compensation, compensation is an expense, real whether or not the headline earnings admit it. One trap: the cash-flow statement adds SBC back, so the operating cash, and the owner earnings drawn from it, are flattered by exactly this amount; counted as the cost it is, what an owner keeps is lower.

Peers, Pharmaceuticals

The same industry, side by side on owner economics. Each figure is a through-cycle median, so a peak or trough year can’t distort it; the group median at the foot is the line to read each against.

CompanyRevenueGross marginOp. marginROICOwner earn. margin
SUPNSupernus Pharmaceuticals Inc.$719M90%20.0%11%26%
KNSAKiniksa Pharmaceuticals International, PLC$678M88%-9.3%-6%5%
RAREUltragenyx$673M100%-154.9%-92%-113%
AXSMAxsome Therapeutics Inc.$638M99%-79.2%-44%
TGTXTG Therapeutics Inc.$616M88%-29896.1%-572%-23443%
OPKOPKO Health Inc.$607M34%-18.8%-8%-13%
INSMInsmed Incorporated$606M77%-202.3%-138%-182%
CPRXCatalyst Pharmaceuticals Inc.$589M86%35.9%48%37%
Group median88%-49.0%-28%
IV

The price

What a price has to assume.

What the price implies

reverse-DCF

Axsome Therapeutics Inc. is profitable, but owner earnings are negative this year because capital spending currently outruns operating cash, a build-out, so the owner-earnings reverse-DCF has no positive base to grow. We read the price from both ends instead: type a price to see the steady-state profitability it demands, then set the mature margin you would believe and weigh the two against each other. Nothing leaves your browser unless you enter it in your notebook.

$
The assumptions

Revenue, delivered122%/yr’22→’25

Enter a price to run it.

Owner earnings it must reach
Margin the price demands
Owner-earnings margin today−10%

Two reads of one future. From your price: the owner earnings the company must reach, valued at a mature multiple and discounted back at your rate, expressed as the margin it implies on revenue grown at your rate. From your belief: the mature margin you would credit, set on the dial above. When the margin the price demands runs above the one you would believe, you are paying for a future taken on faith. For a deep cyclical at a trough, normalized through-cycle earnings are the better lens; this mode is for the genuinely unprofitable, and for the profitable business whose capital spending currently outruns its cash.

Cite: Owner Scorecard, "Axsome Therapeutics Inc. (AXSM), the owner's record," https://ownerscorecard.com/c/AXSM, data as of 2026-07-09.

Manual order: ← AXS its page in the Manual AXTA →

Industry order: ← AVTX the Pharmaceuticals chapter AZN →